GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Starry Pharmaceutical Co Ltd (SHSE:603520) » Definitions » Cyclically Adjusted Revenue per Share

Zhejiang Starry Pharmaceutical Co (SHSE:603520) Cyclically Adjusted Revenue per Share : ¥4.44 (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Zhejiang Starry Pharmaceutical Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zhejiang Starry Pharmaceutical Co's adjusted revenue per share for the three months ended in Jun. 2024 was ¥1.508. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥4.44 for the trailing ten years ended in Jun. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-09-22), Zhejiang Starry Pharmaceutical Co's current stock price is ¥7.41. Zhejiang Starry Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was ¥4.44. Zhejiang Starry Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 1.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zhejiang Starry Pharmaceutical Co was 3.19. The lowest was 1.78. And the median was 2.42.


Zhejiang Starry Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Zhejiang Starry Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Starry Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Zhejiang Starry Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 4.28

Zhejiang Starry Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 4.28 4.41 4.44

Competitive Comparison of Zhejiang Starry Pharmaceutical Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Starry Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Starry Pharmaceutical Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Starry Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zhejiang Starry Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.



Zhejiang Starry Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zhejiang Starry Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=1.508/114.7809*114.7809
=1.508

Current CPI (Jun. 2024) = 114.7809.

Zhejiang Starry Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.000 97.624 0.000
201412 0.000 99.000 0.000
201503 0.827 99.900 0.950
201506 0.643 99.500 0.742
201509 0.489 100.500 0.558
201512 0.853 100.600 0.973
201603 0.693 102.200 0.778
201606 0.580 101.400 0.657
201609 0.470 102.400 0.527
201612 0.487 102.600 0.545
201703 0.586 103.200 0.652
201706 0.609 103.100 0.678
201709 0.467 104.100 0.515
201712 0.489 104.500 0.537
201803 0.583 105.300 0.635
201806 0.980 104.900 1.072
201809 0.849 106.600 0.914
201812 0.782 106.500 0.843
201903 0.883 107.700 0.941
201906 1.073 107.700 1.144
201909 1.015 109.800 1.061
201912 0.980 111.200 1.012
202003 0.866 112.300 0.885
202006 1.319 110.400 1.371
202009 0.986 111.700 1.013
202012 0.930 111.500 0.957
202103 1.047 112.662 1.067
202106 1.492 111.769 1.532
202109 1.294 112.215 1.324
202112 1.976 113.108 2.005
202203 1.547 114.335 1.553
202206 1.250 114.558 1.252
202209 1.436 115.339 1.429
202212 1.877 115.116 1.872
202303 1.774 115.116 1.769
202306 1.340 114.558 1.343
202309 1.491 115.339 1.484
202312 1.957 114.781 1.957
202403 2.092 115.227 2.084
202406 1.508 114.781 1.508

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Zhejiang Starry Pharmaceutical Co  (SHSE:603520) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zhejiang Starry Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.41/4.44
=1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zhejiang Starry Pharmaceutical Co was 3.19. The lowest was 1.78. And the median was 2.42.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zhejiang Starry Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Zhejiang Starry Pharmaceutical Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Starry Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.1 Sitali Avenue, Modern Industrial Gathering District, Zhejiang Province, Xianju County, Taizhou City, CHN, 317306
Zhejiang Starry Pharmaceutical Co Ltd is engaged in R&D, manufacture and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and Fluoroquinolones series.
Executives
Hu Jin Sheng Director

Zhejiang Starry Pharmaceutical Co Headlines

No Headlines